ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER7526850FOR752685FOR ABIVAX SA00370M103US00370M103605/11/2026Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda items.SECTION 14A SAY-ON-PAY VOTESISSUER7526850FOR752685FOR AMYLYX PHARMACEUTICALS, INC.03237H101US03237H101406/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER654610FOR65461FOR ARCUTIS BIOTHERAPEUTICS, INC.03969K108US03969K108806/05/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER848850FOR84885FOR ARROWHEAD PHARMACEUTICALS, INC.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER476860FOR47686FOR AXSOME THERAPEUTICS, INC.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER79440FOR7944FOR BIOHAVEN LTDG1110E107VGG1110E107904/28/2026A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER14409950FOR1440995FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3809400FOR380940FOR BRIDGEBIO PHARMA, INC.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER38094001 YEAR380940FOR CABALETTA BIO, INC.12674W109US12674W109906/09/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER53286010FOR5328601FOR CENTESSA PHARMACEUTICALS PLC152309100US152309100706/12/2026To receive and approve, on an advisory basis, the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2025, which is set forth as Annex A to the attached proxy statement.SECTION 14A SAY-ON-PAY VOTESCOMPENSATIONISSUER3887660FOR388766FOR COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1049350FOR104935FOR CORBUS PHARMACEUTICALS HOLDINGS, INC.21833P301US21833P301005/13/2026Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER22244160FOR2224416FOR CORBUS PHARMACEUTICALS HOLDINGS, INC.21833P301US21833P301005/13/2026To vote, on an advisory basis, on how often the Company will conduct an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER222441601 YEAR2224416FOR CRINETICS PHARMACEUTICALS, INC.22663K107US22663K107906/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;SECTION 14A SAY-ON-PAY VOTESISSUER1454940FOR145494FOR CSTONE PHARMACEUTICALSG2588M100KYG2588M100606/23/2026TO CONSIDER AND APPROVE THE GRANT OF 7,000,000 SHARE OPTIONS AND 4,270,000 RSUS TO DR. JIANXIN YANG, AN EXECUTIVE DIRECTOR AND THE CHIEF EXECUTIVE OFFICER OF THE COMPANYSECTION 14A SAY-ON-PAY VOTESISSUER161248240FOR16124824FOR DAMORA THERAPEUTICS, INC.36322Q206US36322Q206606/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER13036190FOR1303619FOR DAMORA THERAPEUTICS, INC.36322Q206US36322Q206606/17/2026To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER130361901 YEAR1303619FOR DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER3931510FOR393151FOR EDGEWISE THERAPEUTICS INC28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER19222640FOR1922264FOR EYEPOINT, INC.30233G209US30233G209306/18/2026To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER16997890FOR1699789FOR INSMED INCORPORATED457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER328690FOR32869FOR MOONLAKE IMMUNOTHERAPEUTICS61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER31113870FOR3111387FOR NEWAMSTERDAM PHARMA COMPANY N.V.N62509109NL00150012L706/02/2026Non-binding, advisory vote to approve the 2025 compensation of named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER829500FOR82950FOR OLEMA PHARMACEUTICALS, INC.68062P106US68062P106606/17/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER13500940FOR1350094FOR PRAXIS PRECISION MEDICINES, INC.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER3477240FOR347724FOR SENSORION SAF8312Z102FR001259646805/11/2026SETTING OF THE COMPENSATION TO BE ALLOCATED TO THE DIRECTORSSECTION 14A SAY-ON-PAY VOTESISSUER357100000FOR35710000FOR STRUCTURE THERAPEUTICS, INC.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1437920FOR143792FOR TANGO THERAPEUTICS, INC.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10498980FOR1049898FOR TARSUS PHARMACEUTICALS, INC.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1181990FOR118199FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE COMPENSATION POLICY APPLICABLE TO MR. THOMAS LINGELBACH, CEO, FOR THE FISCAL YEAR 2026SECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE INFORMATION REFERRED TO IN ARTICLE L. 22-10-9, I OF THE FRENCH COMMERCIAL CODE, PURSUANT TO ARTICLE L. 22-10-34, I OF THE FRENCH COMMERCIAL CODESECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. THOMAS LINGELBACH, CEOSECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. JUAN CARLOS JARAMILLO, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. PETER BUHLER, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MS. DIPAL PATEL, IN HER CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VALNEVA SEF9635C101FR000405685106/25/2026APPROVAL OF THE FIXED, VARIABLE AND EXCEPTIONAL COMPONENTS MAKING UP THE TOTAL COMPENSATION AND BENEFITS OF ANY KIND PAID DURING, OR GRANTED IN RESPECT OF THE FISCAL YEAR ENDED DECEMBER 31, 2025, TO MR. FRANCK GRIMAUD, IN HIS CAPACITY AS ASSOCIATE MANAGING OFFICERSECTION 14A SAY-ON-PAY VOTESISSUER18134190FOR1813419FOR VAXCYTE, INC.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER117930FOR11793FOR